Maxpro Capital (NASDAQ:JMAC) announced in an 8-K this morning that it has entered into a PIPE agreements adding $23.65 million to its combination with drug developer Apollomics.
Of these, $21.35 million was raised at $10 per share as “Series A preferred shares”. These will be convertible into 1.25 common shares each and will be locked up for six months. An additional $2.3 million PIPE was raised at $10 per share without these benefits, but these shares are to come with a 1/4 warrant attached that may be exercised between six months and five years out from close.
The parties originally announced their $932 million deal in September 2022. Foster City, California-based Apollomics is developing a line of drug candidates to treat rare cancers with clinical processes nearing completion in both the US and Chinese treatment markets.
In November, it received an orphan drug designation for its APL-101 drug candidate, which is in Phase II trials to potentially treat non-small cell lung cancer and other cancer types.
Maxpro has a transaction deadline coming up on April 13 and it has already used its two automatic extensions.
In January 2025, SPAC teams continued extending beyond their third round, with one SPAC notably reaching its seventh extension vote as they searched for suitable deals. The month saw five announcements, marking the highest level in recent months, while only four SPACs held completion votes. Extension Votes In January, 14 extension votes were scheduled, representing...
At the SPAC of Dawn February is set to start with the jolt of a new potential trade war in North America. While some observers had expected tough trade action on China, the incoming administration’s decision to begin with 25% tariffs on the US’ biggest trading partners and neighbors, Mexico and Canada, and tariffs of...
Terms Tracker for the Week Ending January 31, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. This past week saw three new SPAC IPOs price, bringing the January and year-to-date IPO count to eight and underlining an active start to 2025....
The shortest month of the year nonetheless features new liquidity events for nine SPAC sponsors and 10 de-SPACs that at least a trio of which can be excited about. The de-SPACs being released from lock-ups this month with most to gain will also in most cases be the ones that will have to wait until...
Fifth Era Acquisition Corp I (NASDAQ:FERAU) has filed for a $200 million SPAC to potentially make another run at a blockchain or crypto transaction after the team’s first attempt fell short of sealing a deal. The new SPAC is offering investors a right to a 1/10 share in each unit, but it is not overfunded...